Ocular Therapeutix Q2 net loss $(43.8)M; AXPAXLI SOL-R accepted as pivotal trial

OCULAR THERAPEUTIX, INC

2024-Q2 EPS reported -$0.73 revenue$31,215,000

Net loss of $(43.8)M ($(0.26)/share) vs $(20.7)M ($(0.26)/share) in Q2 2023; revenue $16.4M (+8.3% YoY).
Cash $459.7M as of June 30, 2024; expected to fund operations into 2028.
FDA confirmed SOL-R repeat dosing study (Phase 3 wet AMD) is appropriate as second registrational trial; ~825 subjects to be randomized.
SOL-1 enrollment accelerating: 151 subjects enrolled as of June 7, 2024, 60 active sites.
HELIOS Phase 1 NPDR data showed DRSS improvement; no intraocular inflammation; presented at ASRS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.